Factors associated with treatment adherence in a randomised trial of latent tuberculosis infection treatment

International Journal of Tuberculosis and Lung Disease

Volumn 14, Issue 5, 2010, Pages 551-559

  Trajman, A ^a   Long, R ^b   Zylberberg, D ^a   Dion, M J ^c   Al Otaibi, B ^d   Menzies, D ^c  

^a GAMA FILHO UNIVERSITY   (Brazil)

^b UNIVERSITY OF ALBERTA   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

Author keywords

Adherence; Compliance; Isoniazid; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; RIFAMPICIN;

ADULT; AGED; ARTICLE; BRAZIL; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SELF ADMINISTRATION; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; NEURITIS; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAUDI ARABIA; SKIN MANIFESTATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; BRAZIL; CANADA; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISONIAZID; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RIFAMPIN; RISK; SAUDI ARABIA; TIME FACTORS; TUBERCULOSIS; YOUNG ADULT;

EID: 77950902618     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. World Health Organization. WHO Three I's meeting: intensi-f ed case f nding (ICF), isoniazid preventive therapy (IPT) and TB infection control (IC) for people living with HIV. Report of a Joint World Health Organization HIV/AIDS and TB Department meeting. 2-4 April, 2008, Geneva, Switzerland. Geneva, Switzerland: WHO, 2008.
2. International Union Against Tuberculosis Committee on Prophylaxis. Eff cacy of various durations of isoniazid preventive therapy for tuberculosis: f ve years of follow-up in the IUAT trial. Bull World Health Organ 1982; 60: 555-564.
3. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. Adv Tuberc Res 1969; 17: 28-106.
4. Smieja M, Marchetti C, Cook D, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000: CD001363.
5. Hirsch-Moverman Y, Daftary A, Franks J, Colson P W. Adherence to treatment for latent tuberculosis infection: systematic review of studies in US and Canada. Int J Tuberc Lung Dis 2008; 12: 1235-1254.
6. Dash L A, Comstock G W, Flynn J P G. Isoniazid preventive therapy. Am Rev Respir Dis 1980; 121: 1039-1044.
7. Lauzardo M. LTBI treatment completion rates in Florida in 2001-2002 [unpublished report]. Tallahassee, FL, USA: Florida State Health Department, 2004.
8. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (Pt 2): S221-S247. (Pubitemid 30233180)
9. Dash L A, Comstock G W, Flynn J P. Isoniazid preventive therapy: retrospect and prospect. Am Rev Respir Dis 1980; 121: 1039-1044.
10. Lardizabal A, Passannante M, Kojakali F, Hayden C, Reich-man L B. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Chest 2006; 130: 1712-1717. (Pubitemid 46033423)
11. Hasker E, Khodjikhanov M, Usarova S, et al. Default from tuberculosis treatment in Tashkent, Uzbekistan; who are these defaulters and why do they default? BMC Infect Dis 2008; 8: 97-103.
12. Rennie T W, Bothamley G H, Engova D, Bates I P. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007; 30: 728-735. (Pubitemid 351194834)
13. Munseri P J, Talbot E A, Mtei L, Fordham von Reyn C. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis 2008; 12: 1037-1041.
14. Szakacs T A, Wilson D, Cameron D W, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 2006; 6: 97-103. (Pubitemid 44083841)
15. Centers for Disease Control and Prevention. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in the American Thoracic Society/CDC recommendations. MMWR 2001; 50 (34): 733-735.
16. Hong Kong Chest Service Tuberculosis Research Centre MBMRC. A double-blind placebo-controlled clinical trial of three anti-tuberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145: 36-41.
17. Long R E. Canadian tuberculosis standards. 2000/2001 ed. T oronto, ON, Canada: Canadian Lung Association, 2000.
18. Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med 2008; 149: 689-697.
19. Cramer J A, Mattson R H, Prevey M L, Scheyer R D, Ouellette V L. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-3277.
20. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497. (Pubitemid 41127293)
21. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15.
22. Page K R, Sifakis F, Montes de Oca R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
23. Pina-Gutiérrez J M, Ferrer Traid A, Arias C, Sala-Ferré M R, López Sanmartín J L. Adherence and effectiveness of the treatment of latent tuberculosis infection with isoniazid for 9 months in a cohort of 755 patients. Med Clin (Barc) 2008; 130: 165-171.
24. Menzies D, Dion M J, Francis D, et al. In closely monitored patients, adherence in the f rst month predicts completion of therapy for latent tuberculosis infection. Int J Tuberc Lung Dis 2005; 9: 1343-1348. (Pubitemid 43265143)
25. Gao X F, Wang L, Liu G J, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis 2006; 10: 1080-1090. (Pubitemid 44519344)
26. Comstock G W, Hammes L M, Pio A. Isoniazid prophylaxis in Alaskan boarding schools. Am Rev Respir Dis 1969; 100: 773-779.
27. Comstock G M. How much isonizid is needed for prevention of tuberculosis in immunocompetent adults? Int J Tuberc Lung Dis 1999; 3: 847-850.
28. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis 2004; 39: 566-568. (Pubitemid 39120936)
29. Storms W. Clinical trials: are these your patients? J Allerg Clin Immunol 2003; 112 (Suppl 5): S107-S111.
30. Parsyan A E, Saukkonen J, Barry M A, Sharnprapai S, Hors-burgh C R Jr. Predictors of failure to complete treatment for latent tuberculosis infection. J Infect 2007; 54: 262-266. (Pubitemid 46238167)
31. Shieh F K, Snyder G, Horsburgh C R, Bernardo J, Murphy C, Saukkonen J J. Predicting non-completion of treatment for latent tuberculosis infection: a prospective survey. Am J Respir Crit Care Med 2006; 174: 717-721. (Pubitemid 44395341)
32. Urquhart J. Role of patient compliance in clinical pharmaco-kinetics. A review of recent research. Clin Pharmacokinet 1994; 27: 202-215. (Pubitemid 24280233)
33. Riska N V, Mattson K. Systemic reactions to intermittent ri-fampicin. Bull Int Union Tuberc 1974; 49 (Suppl 1): 280-285.
34. Nessi R, Bonoldi G L, Redaelli B, di Filippo G. Acute renal failure after rifampicin: a case report and survey of the literature. Nephron 1976; 16: 148-159.